• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG; ENZYME LINKED IMMUNOABSORBENT ASSAY, TOXOPLASMA GONDII

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG; ENZYME LINKED IMMUNOABSORBENT ASSAY, TOXOPLASMA GONDII Back to Search Results
Model Number N/A
Medical Device Problem Code Non Reproducible Results (4029)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 02/06/2024
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
An outside the us customer contacted a siemens customer care center to report imprecise toxoplasma quantitative igg results on a patient sample on an immulite 2000 xpi instrument.Quality control results were within range on the dates of testing.The limitations section of the immulite 2000 toxoplasma quantitative igg assay instructions for use (ifu) states: "the use of immulite 2000 toxoplasma quantitative igg to diagnose recent infection by testing paired sera has not been validated.The results of the test must be taken within the context of the patient's clinical history, symptomology and other laboratory findings." siemens is investigating.
 
Event or Problem Description
Imprecise toxoplasma quantitative igg results were obtained on a patient sample on an immulite 2000 xpi instrument.The initial results were reported to the physician(s) who questioned the results.The sample was repeated in multiple replicates on the same immulite 2000 xpi on the date of initial testing and was repeated on the same immulite 2000 xpi on a different date.The repeat replicates from both event dates remained imprecise with some replicates resulting reactive and some replicates resulting as nonreactive.Per the customer, the true result remains "unclear".There are no known reports of patient intervention or adverse health consequences due to the imprecise toxoplasma quantitative igg results.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 1219913-2024-00040 on 28-feb-2024.Additional information 23-may-2024: an internal study was performed with immulite 2000 toxoplasma quantitative igg kit lot 523 on the immulite 2000 xpi system.Testing summary: immulite 2000 toxoplasma quantitative igg kit lot 523 was adjusted with kitted adjustors on an immulite 2000 xpi instrument.Immulite 2000 toxoplasma quantitative igg controls lot 0152 were measured on 5 days in replication of five.4 prescreened patient samples were measured on 5 days in replication of five.Immulite 2000 toxoplasma quantitative igg lot 523 was successfully adjusted.Immulite 2000 toxoplasma quantitative igg controls lot 0152 resulted within the stated ranges.Siemens is continuing to evaluate available data for immulite 2000 toxoplasma quantitative igg kit lot 523.The customer is operational.Immulite 2000 toxoplasma quantitative igg kit lot 523 expired on 30-apr-2024 and is no longer in use.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 1219913-2024-00040 on 28-feb-2024.Siemens filed supplemental mdr 1219913-2024-00040-s1 on 19-jun-2024.Additional information 21-jun-2024: siemens has replicated the customer's observation of imprecision with some patient sample results when using immulite 2000 toxoplasma quantitative igg lot 523.Preanalytical factors cannot be ruled out.The investigation is ongoing.
 
Additional Manufacturer Narrative
Siemens filed the initial mdr 1219913-2024-00040 on 28-feb-2024.Siemens filed mdr 1219913-2024-00040 supplemental report 1 on 19-jun-2024.Siemens filed mdr 1219913-2024-00040 supplemental report 2 on 11-jul-2024.Additional information 14-aug-2024: siemens investigated the report of sample imprecision with immulite toxoplasma quantitative igg lot 523.Using lot 523, siemens tested quality control (qc) and four patient samples across five days in replicates of five with 5.4-32.51% cvs.Assessment of individual replicates suggests that the imprecision is caused by sporadic elevated results in these samples.It is also observed that the % cvs are not consistent across similar dosing samples e.G., patient samples with mean doses of 11.2 iu/ml) and 10.2 iu/ml show within-run precision at 26.52% cv and 13.42% cv, respectively.Therefore, pre-analytical factors cannot be ruled out.Qc data is within expectations for precision.Reviewing internal release criteria shows that bead precision met specification and assessment of calibrators relative to counts per second (cps) are within specification with no fliers being observed in these datasets.Internal data for qc and calibrators are not showing imprecision for immulite 2000 xpi toxoplasma quantitative igg lot 523 which expired 30-apr-2024.Further investigation was not possible.Immulite 2000 xpi toxoplasma quantitative igg lot 526 is the only kit lot currently available.To determine whether imprecision is seen on lot 526, siemens tested qc and patient samples in replicates of 20 with 6 to 16% cvs observed.Qc data is within expectations for repeatability (intra-assay) precision.Patient samples with mean doses of 7.2 iu/ml, 11 iu/ml, 57 iu/ml, 81 iu/ml, and 177 iu/ml perform within expectation for repeatability (intra-assay) precision.Two patient samples with mean doses of 6.6 iu/ml and 7.6 iu/ml were observed to have a 15% cv and a 16% cv for repeatability (intra-assay) precision, respectively.To further rule out imprecision with current lot 526, an expanded review of internal data was performed.The average intra-assay precision for calibrators at the low end of the assay is within expectations.Internal data for qc and calibrators are not showing imprecision.Internal data is within expectations for within-lab (inter-assay)/total precision.There is not a systemic failure of samples with doses at the low end of the assay range.An imprecision issue with immulite 2000 xpi toxoplasma quantitative igg lot 526 has not been identified.Siemens cannot rule out preanalytical factors as a possible cause of the observed imprecision.Based on the available information, a product problem has not been identified.In section d4, the primary udi number was updated to include the corrected unique device identifier (udi) number.The initial mdr contained only the global trade item number (gtin).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMMULITE 2000 TOXOPLASMA QUANTITATIVE IGG
Common Device Name
ENZYME LINKED IMMUNOABSORBENT ASSAY, TOXOPLASMA GONDII
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
glyn rhonwy, gwynedd
uk registration #: 3002806944
llanberis LL554 EL
UK  LL554EL
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
glyn rhonwy, gwynedd
uk registration #: 3002806944
llanberis LL554 EL
UK   LL554EL
Manufacturer Contact
jennifer cacace
333 coney st.
east walpole, MA 02032
8024302902
MDR Report Key18800305
Report Number1219913-2024-00040
Device Sequence Number7310651
Product Code LGD
UDI-Device Identifier00630414962238
UDI-Public(01)00630414962238(10)523(17)240430
Combination Product (Y/N)N
Initial Reporter CountryUP
PMA/510(K) Number
K962936
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup,Followup
Report Date (Section B) 08/16/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date04/30/2024
Device Model NumberN/A
Device Catalogue Number10381323
Device Lot Number523
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Follow-Up
Initial Date Received by Manufacturer 02/09/2024
Supplement Date Received by Manufacturer05/23/2024
06/21/2024
08/14/2024
Initial Report FDA Received Date02/28/2024
Supplement Report FDA Received Date06/19/2024
07/11/2024
08/22/2024
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured10/12/2023
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-